Osimertinib

Grey

Brand Name(s):TAGRISSO

Indication:Cancer – non-small-cell lung

Rationale:2

Considered:Feb-16

Review Date:Feb-25

Comments:
Osimertinib is not recommended for untreated locally advanced or metastatic EGFR+ve NSCLC as the most plausible cost-effectiveness estimates are above what is considered an acceptable use of NHS resources and it does not meet the criteria to be included in the Cancer Drugs Fund.
https://www.nice.org.uk/guidance/ta621

NICE TA 416
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oct 2016